カレントテラピー 30-5 サンプル

カレントテラピー 30-5 サンプル page 23/38

電子ブックを開く

このページは カレントテラピー 30-5 サンプル の電子ブックに掲載されている23ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要:
化学療法と放射線療法colon cancer:results of a randomized trial. J Clin Oncol 21:2896 -2903, 20033)Lembersky BC, Wieand HS, Petrelli NJ, et al:Oral uracil andtegafur plus leucovorin compared with i....

化学療法と放射線療法colon cancer:results of a randomized trial. J Clin Oncol 21:2896 -2903, 20033)Lembersky BC, Wieand HS, Petrelli NJ, et al:Oral uracil andtegafur plus leucovorin compared with intravenous fluorouraciland leucovorin in stageⅡandⅢcarcinoma of thecolon:results from National Surgical Adjuvant Breast andBowel Project Protocol C -06. J Clin Oncol 24:2059-2064,20064)Twelves C, Wong A, Nowacki MP, et al:Capecitabine asadjuvant treatment for stageⅢcolon cancer. N Engl J Med352:2696-2704, 20055)Sakamoto J, Ohashi Y, Hamada C, et al;Meta -AnalysisGroup of the Japanese Society for Cancer of the Colon andRectum and the Meta-Analysis Group in Cancer:Efficacy oforal adjuvant therapy after resection of colorectal cancer:5 -year results from three randomized trials. J Clin Oncol22:484-492, 20046)Andre T, Boni C, Navarro M, et al:Improved overall survivalwith oxaliplatin, fluorouracil, and leucovorin as adjuvanttreatment in stageⅡorⅢcolon cancer in the MOSAICtrial. J Clin Oncol 27:3109-3116, 20097)Schmoll HJ, Cartwright T, Tabernero J, et al:PhaseⅢtrialof capecitabine plus oxaliplatin as adjuvant therapy for stageⅢcolon cancer:a planned safety analysis in 1,864 patients. JClin Oncol 25:102 -109, 20078)Van Cutsem E, Labianca R, Bodoky G, et al:RandomizedphaseⅢtrial comparing biweekly infusional fluorouracil/leucovorinalone or with irinotecan in the adjuvant treatment ofstageⅢcolon cancer:PETACC -3. J Clin Oncol 27:3117 -3125, 20099)Ychou M, Raoul JL, Douilard JY, et al:A phaseⅢrandomisedtrial of LV5FU2+irinotecan versus LV5FU2 alonein adjuvant high -risk colon cancer(FNCLCC Accord02/FFCD9802). Ann Oncol 20:674-680, 200910)Hamaguchi T, Shirao K, Moriya Y, et al:Final results of randomizedtrials by the National Surgical Adjuvant Study ofColorectal Cancer(NSAS -CC). Cancer Chemother Pharmacol67:587-596, 201111)West NP, Hohenberger W, Weber K, et al:Complete mesocolicexcision with central vascular ligation produces anoncologically superior specimen compared with standard surgeryfor carcinoma of the colon. J Clin Oncol 28:272 -278,201012)Allegra CJ, Yothers G, O’Connell MJ, et al:PhaseⅢtrialassessing bevacizumab in stagesⅡandⅢcarcinoma of thecolon:results of NSABP protocol C -08. J Clin Oncol 29:11-16, 201113)de Gramont A, Van Custem E, Taberbero J, et al:AVANT:Results from a randomized, three -arm multinational phaseIII study to investigate bevacizumab with either XELOX orFOLFOX4 alone as adjuvant treatment for colon cancer.2011 Gastrointestinal Cancers Symposium. J Clin Oncol 29(suppl 4):2011(abstr 362)14)Alberts SR, Sargent DJ, Smyrk TC, et al:Adjuvant mFOLF-OX6 with or without cetuximab(Cmab)in KRAS wild-type(WT)patients(pts)with resected stageⅢcolon cancer(CC):Results from NCCTG Intergroup PhaseⅢTrialN0147. 2010 ASCO Annual Meeting. J Clin Oncol 28(suppl18):2010(abstr CRA3507)15)Kato T, Ohashi Y, Nakazato H, et al:Efficacy of oral UFT asadjuvant chemotherapy to curative resection of colorectalcancer:multicenter prospective randomized trial. Langenbeck’sArch Surg 386:575-581, 200216)Aschele C, Cionini L, Lonardi S, et al:Primary tumorresponse to preoperative chemoradiation with or withoutoxaliplatin in locally advanced rectal cancer:pathologicresults of the STAR -01 randomized phaseⅢtrial. J ClinOncol 29:2773 -2780, 201117)Yothers G, O’Connell MJ, Allegra CJ, et al:Oxaliplatin asadjuvant therapy for colon cancer:updated results ofNSABP C-07 trial, including survival and subset analyses. JClin Oncol 29:3768-3774, 201118)Yothers GA, Allegra CJ, O’Connell MJ, et al:The efficacy ofoxaliplatin(Ox)when added to 5-fluorouracil/leucovorin(FU/L)in stage II colon cancer. 2011 ASCO Annual Meeting. JClin Oncol 29:2011(abstr 3507)19)Chau I, Norman AR, Cunningham D, et al:A randomisedcomparison between 6 months of bolus fluorouracil/leucovorinand 12 weeks of protracted venous infusion fluorouracilas adjuvant treatment in colorectal cancer. Ann Oncol 16:549-557, 200520)Neugut AI, Matasar M, Wang X, et al:Duration of adjuvantchemotherapy for colon cancer and survival among theelderly. J Clin Oncol 24:2368-2375, 2006Current Therapy 2012 Vol.30 No.543561